Managed Healthcare Executive
CONTINUE TO SITE >

OR WAIT 15 SECS

  • Formulary WatchFormulary Watch
  • Managed Healthcare Executive
  • Medical EconomicsMedical Economics
  • Physicians PracticePhysicians Practice
Managed Healthcare Executive
Managed Healthcare Executive
Resource Centers
View MoreAutoimmuneCardiovascular DiseasesDiabetesEyecareHIVLung Cancer - NSCLCLiver DiseaseUrothelial Carcinoma
Spotlight
Multiple SclerosisEyecareThe Improving Patient Access PodcastHow to Reduce Maternal, Infant Health Risks During COVID-19
Business
View MoreBusiness StrategyConsumersDrug CostsDrug PipelineFormularyHealth ManagementHealth/Disease StrategyHospitals & ProvidersIndustry AnalysisPharmacyPolitics and PolicyPractice ManagementReimbursementTechnology
News
Media
Expert Interviews
K-Cast
Medical World News
Podcasts
Population Health Perspectives
Conferences
Publications
MHE Publication
Supplements And Featured Publications
CME/CE
Resources
Sponsored
Surveys
Subscribe
eNewsletter
Print Subscription
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Informations

© 2021 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.

Resource CentersSee All >
  • Autoimmune
  • Cardiovascular Diseases
  • Diabetes
  • Eyecare
  • HIV
  • Lung Cancer - NSCLC
  • Liver Disease
  • Urothelial Carcinoma
Spotlight
  • Multiple Sclerosis
  • Eyecare
  • The Improving Patient Access Podcast
  • How to Reduce Maternal, Infant Health Risks During COVID-19
BusinessSee All >
  • Business Strategy
  • Consumers
  • Drug Costs
  • Drug Pipeline
  • Formulary
  • Health Management
  • Health/Disease Strategy
  • Hospitals & Providers
  • Industry Analysis
  • Pharmacy
  • Politics and Policy
  • Practice Management
  • Reimbursement
  • Technology
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Informations
  • MJHLS Brand Logo

© 2021 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.

Andrew Dreyfus promoted to president and CEO of BCBS of Massachusetts

September 15, 2010

The Board of Directors of Blue Cross Blue Shield of Massachusetts (BCBSMA) has chosen Executive Vice President Andrew Dreyfus as the company's new president and chief executive officer. Dreyfus succeeds Bill Van Faasen who has served in an unpaid interim role of president and CEO since March 16, 2010.

The Board of Directors of Blue Cross Blue Shield of Massachusetts (BCBSMA) has chosen Executive Vice President Andrew Dreyfus as the company's new president and chief executive officer. Dreyfus succeeds Bill Van Faasen who has served in an unpaid interim role of president and CEO since March 16, 2010. Van Faasen will remain involved with the company in a role still to be determined.

"Andrew is not only an experienced leader in the industry and a nationally known expert on critical issues such as health reform and changing the way we pay for care, but as importantly, he has a broad understanding and passionate commitment to continuing and strengthening the important leadership role BCBSMA has played in our community since the company's founding 73 years ago," said BCBSMA Board Chairman Paul Guzzi in a statement announcing the decision.

Over the past five years, Dreyfus has served as BCBSMA's executive vice president for Health Care Services. He also led the development and execution of the company's Alternative Quality Contract (AQC), a new payment model that aligns physician and hospital payments with the quality of care patients receive.

Dreyfus has been a part of BCBSMA's executive leadership team since 2001, when he was selected as the first president of the Blue Cross Blue Shield of Massachusetts Foundation. Prior to joining BCBSMA in 2001, Dreyfus was an executive vice president at the Massachusetts Hospital Association and held senior positions in the Massachusetts Executive Office of Human Services and the Executive Office of Consumer Affairs and Business Regulation.